Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

Paller, Amy S.; Tom, Wynnis L.; Lebwohl, Mark; Blumenthal, Robin L.; Boguniewicz, Mark; Call, Robert S.; Eichenfield, Lawrence F.; Forsha, Douglass W.; Rees, William C.; Simpson, Eric L.; Spellman, Mary; Gold, Linda Stein; Zaenglein, Andrea L.; Hughes, Matilda H.; Zane, Lee T.; Hebert, Adelaide A.

doi:10.1016/j.jaad.2016.05.046

articleJournal of the American Academy of DermatologyJul 11, 2016HYBRID OA

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

ASAmy S. Paller WLWynnis L. Tom MLMark Lebwohl RLRobin L. Blumenthal MBMark Boguniewicz

Northwestern University · Rady Children's Hospital-San Diego · +10 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Background

Additional topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks.

Objective

We sought to assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, in two phase III AD studies (AD-301: NCT02118766; AD-302: NCT02118792).

Citation impact

558

total citations

FWCI: 66.46
Percentile: 100%
References: 53

Citations per year

Authors

16

Topics & keywords

Topics

Keywords

Medicine
Atopic dermatitis
Adverse effect
Clinical endpoint
Internal medicine
Dermatology
Randomized controlled trial

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.